Drug Information

Drug General Information
Drug ID
D0CA9H
Former ID
DNC008972
Drug Name
N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529703]
Structure
Download
2D MOL

3D MOL
Formula
C29H35N3O
Canonical SMILES
C1CN(CCN1CCCCCC(=O)NCC2=CC=CC=C2)C3=CC=CC=C3C4=CC=CC=C4
InChI
1S/C29H35N3O/c33-29(30-24-25-12-4-1-5-13-25)18-8-3-11-19-31-20-22-32(23-21-31)28-17-10-9-16-27(28)26-14-6-2-7-15-26/h1-2,4-7,9-10,12-17H,3,8,11,18-24H2,(H,30,33)
InChIKey
LQFAQQWXFSOOQJ-UHFFFAOYSA-N
PubChem Compound ID
25107518
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Inhibitor [529703]
5-hydroxytryptamine 1A receptor Target Info Inhibitor [529703]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholismhsa04024:cAMP signaling pathway
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Dopamine receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic NeuronsWP722:Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
References
Ref 529703J Med Chem. 2008 Sep 25;51(18):5813-22.Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.
Ref 529703J Med Chem. 2008 Sep 25;51(18):5813-22.Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.